TABLE 2

Fasting metabolic profile of islet cell Ab and Ab+ obese youth clinically diagnosed with type 2 diabetes and obese control subjects

Clinically diagnosed type 2 diabetic patients
Obese control subjectsP value
AbAb+ANOVAPost hoc
n162639
Glucose (mmol/l)6.6 ± 0.4 (4.6–9.5)7.4 ± 0.4 (5.0–13.5)5.4 ± 0.1 (4.8–6.2)<0.001NS
Insulin (pmol/l)274 ± 37 (77–690)183 ± 20 (49–472)249 ± 18 (95–573)0.030.05
HGP (μmol · kg−1 · min−1)13.3 ± 0.6 (10.1–18.0)16.1 ± 1.1 (9.2–34.1)13.1 ± 0.5 (9.2–25.5)0.02NS
Glucose oxidation (μmol · kg−1 · min−1)6.5 ± 0.7 (3.8–11.4)7.4 ± 0.7 (2.5–17.8)8.6 ± 0.6 (3.1–16.1)0.09NS
Fat oxidation (μmol · kg−1 · min−1)4.7 ± 0.4 (2.2–7.8)4.3 ± 0.3 (1.4–7.5)4.1 ± 0.2 (2.1–8.8)NSNS
Free fatty acid baseline (μmol/l)439 ± 23 (252–598)427 ± 24 (216–678)341 ± 18 (161–607)0.003NS
Cholesterol (mmol/l)3.9 ± 0.2 (2.5–5.0)3.9 ± 0.1 (2.9–5.6)4.4 ± 0.9 (2.3–6.6)0.03NS
HDL (mmol/l)0.96 ± 0.04 (0.65–1.33)0.99 ± 0.04 (0.67–1.69)1.06 ± 0.03 (0.70–1.53)NSNS
LDL (mmol/l)2.3 ± 0.2 (1.3–3.1)2.4 ± 0.1 (1.4–4.3)2.7 ± 0.1 (1.1–4.5)0.04NS
Triglycerides (mmol/l)1.5 ± 0.2 (0.6–3.9)1.3 ± 0.1 (0.6–3.4)1.3 ± 0.1 (0.6–4.3)NSNS
VLDL (mmol/l)0.31 ± 0.04 (0.11–0.79)0.26 ± 0.03 (0.11–0.67)0.28 ± 0.03 (0.11–0.86)NSNS
  • Data are means ± SEM (range). Post hoc P value, Bonferonni correction for Ab vs. Ab+ clinically diagnosed type 2 diabetic patients.